The wearable technology industry recently saw a significant regulatory shift that paved the way for new features on devices like the Google Pixel Watch 5. This change follows a legal dispute between the fitness tracker company Whoop and the Federal Food and Drug Administration.
In 2025, the FDA issued a warning to Whoop, claiming their Blood Pressure Insights feature functioned as a medical device without proper clearance. Whoop disputed this, arguing that the feature served only as a wellness tool rather than a diagnostic one. They stood their ground on the principle that consumers should access their own health data without unnecessary regulatory interference.
This confrontation led the FDA to issue updated guidance in early 2026. The agency clarified that non-invasive wearable products outputting physiologic parameters like blood pressure can qualify as general wellness tools, provided their intent remains strictly non-medical. This distinction allows companies to offer broader health trend insights without the lengthy clearance process required for medical-grade equipment.
Following this clarification, Google introduced its own Blood Pressure Trends feature. Unlike medical-grade monitors, the Pixel Watch 5 uses passive tracking to report monthly trends rather than real-time clinical readings. This approach mirrors the framework established during the Whoop conflict.
Industry analysts note that this outcome benefits more than just Whoop. By defining clear boundaries for wellness technology, the regulator has reduced friction for manufacturers looking to integrate advanced health tracking into everyday wearables. This ensures that while medical devices remain strictly controlled, consumer electronics can continue to provide users with meaningful health information.